A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 332 participants.

Also called NCT07301034

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 332 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07301034
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Austria, Denmark, Italy, Netherlands, Spain, Switzerland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07301034. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-18 (actual); primary completion 2028-11-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
Acronym
ZEPHYR
Intervention (Drug)
Ziltivekimab
Intervention (Drug)
Ziltivekimab Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07301034
Content hash
0b0a7534250f5b6f8328e851da9011a86782d335c0d70e03eb758c406f6e017b